Novartis has expanded its collaboration with Monte Rosa Therapeutics, investing $120 million upfront for rights to a new molecular glue degrader targeting immune-mediated diseases. This second agreement builds on their 2024 deal and includes options to license two additional preclinical programs. With total potential milestone and sales payments reaching $5.7 billion, Novartis signals strategic commitment to protein degradation as a therapeutic modality. Monte Rosa gains vital capital to advance multiple programs, including phase 2 trials for autoimmune indications. This partnership exemplifies pharma's growing interest in molecular glues—small molecules that induce targeted protein degradation to address challenging disease pathways.